Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: NUMIF )

0.0400 -0.0134 (-25.09%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NUMIF

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
American Billionaire Entrepreneurs Bet Millions on Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman... 
Via FinancialNewsMedia
Exposures Product Safety
Novamind To Offer Virtual Mental Health Therapy Sessions
Novamind (OTCQB: NVMDF), which is to be acquired by Numinus Wellness (OTCMKTS: NUMIF), recently announced a collaboration with health coaching platform HealCommunit 
Via Benzinga
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
Numinus to Acquire Novamind For $20.74M In Stock
Via Benzinga
Numinus Wellness Strives To Become Psychedelic Research Hub After Acquisition Of Novamind Inc.
In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action. 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19%
An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the... 
Via Talk Markets
Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS
Numinus Wellness Inc. (OTCQX: NUMIF), announced that clinical trial MAPPUSX has gotten underwaywith the enrolling and dosing ... 
Via Benzinga
Demand for Toad Venom Rises Along With the Booming Psychedelics Market
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 – Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic... 
Via FinancialNewsMedia
Psychedelic Compounds-Based Drug Stocks Down Slightly This Past Week
We're tracking 13 public companies (US and/or Canada) doing clinical-stage research into THC and/or psychedelics for treating mental illnesses. While a few were up this week, the overall trend... 
Via Talk Markets
Cannabis Movers & Shakers: TGOD, Numinus Wellness, GTI, Neptune Wellness
The Green Organic Dutchman Names New CFO The Green Organic Dutchman Holdings Ltd. (CSE: 
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,... 
Via Benzinga
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE. 
Via Benzinga
Psychedelic Stocks Finally In An Upswing
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week. 
Via Talk Markets
Psychedelics Co. Numinus Wellness Appoints New Bioscience Advisors To Bolster IP Development
Psychedelics-focused company Numinus Wellness Inc. (TSX:NUMI) (OTCQX: NUMIF) announced the appointment of three key advisors to its new Bioscience Advisory Board. 
Via Benzinga
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri
Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychede... 
Via Benzinga
Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD
This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a... 
Via Talk Markets
Numinus Wellness Reveals 244.5% YoY Improvement In Q1 Revenue & Wider Loss
Numinus Wellness Inc (TSX:NUMI) (OTC: 
Via Benzinga
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of... 
Via FinancialNewsMedia
Marijuana & Psychedelic Drug Stocks Continue To Decline
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 16 of the 100 such companies that trade on North American stock exchanges. 5 of them are marijuana drug stocks and 11 are... 
Via Talk Markets
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents. 
Via Talk Markets
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Psychedelics Company Numinus Wellness Q4 Revenue Grows 81% YoY Thanks To Mindscape Acquisition
Psychedelics-focused mental health care company Numinus Wellness Inc. (TSXV: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.